Cancer diagnostics developer Angle (LON: AGL) reported 2022 figures in line with expectations, but the strong prospects for the Parsortix system and services, plus the cash pile have led to a jump in the AIM-quoted share price is 19.5% higher at 24.5p. Parsortix is the first system that harvests circulating cancer cells from a blood […]

The post Angle shares bounce back on Parsortix prospects appeared first on UK Investor Magazine.

It seems to have taken ages, but the FDA has finally given approval for the Parsortix liquid biopsy test developed by ANGLE (LON: AGL). The share price jumped 58% in the afternoon to 156p, which is the highest it has been since 2005, when it was a different business with a portfolio of investee companies. […]

The post Angle gains FDA approval for Parsortix appeared first on UK Investor Magazine.

Cancer diagnostics developer ANGLE (LON: AGL) is getting nearer to FDA approval for its Parsortix liquid biopsy test. Angle would be the first company to receive FDA Class II clearance for a device harvesting intact circulating tumour cells CTC), making the technology highly valuable. The specific approval would cover breast cancer. Clearance would allow Parsortix […]

The post ANGLE moves towards Parsortix FDA approval appeared first on UK Investor Magazine.